Stock DNA
Specialty Chemicals
INR 4,029 Cr (Small Cap)
14.00
37
0.53%
0.24
12.05%
1.72
Total Returns (Price + Dividend) 
Latest dividend: 2.5 per share ex-dividend date: Feb-07-2025
Risk Adjusted Returns v/s 
Returns Beta
News

Epigral Ltd is Rated Sell
Epigral Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 28 September 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 November 2026, providing investors with the latest insights into the company’s performance and outlook.
Read More
Epigral Ltd Surges 7.77% to Day's High of Rs 951 — Outperforms Sector by 5.4 Percentage Points
The Sensex advanced 1.49% on 11 Nov 2026, yet Epigral Ltd outpaced the broader market with a 7.77% gain, touching an intraday high of Rs 951. This 5.4 percentage-point outperformance over its Specialty Chemicals sector peers signals a distinctly stock-specific rally rather than a mere market tailwind.
Read More
Epigral Ltd Surges 8.64% to Day's High of Rs 942.65 — Outperforms Sector by 6.98 Percentage Points
The Sensex advanced 0.98% on 2 Nov 2026, yet Epigral Ltd outpaced the broader market with an 8.64% gain, reaching an intraday high of Rs 942.65. This 6.98-percentage-point outperformance over its Specialty Chemicals sector peers marks a notable single-session surge that rewrites the short-term narrative for this small-cap stock.
Read More Announcements 
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
17-Nov-2026 | Source : BSEOne-on-One Meeting through Video Conferencing (V.C.) with Kitara Capital on Friday 20th November 2026.
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
17-Nov-2026 | Source : BSEOne-on-One Meeting through Video Conferencing (V.C.) with Kotak Mahindra Asset Management (Singapore) Pte Ltd on Thursday 19th November 2026.
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
07-Nov-2026 | Source : BSEEpigral Limited submits Transcript of conference call held on Monday 2nd November 2026 discussing Q2 FY2027 Results.
Corporate Actions 
No Upcoming Board Meetings
Epigral Ltd has declared 50% dividend, ex-date: 01 Jun 26
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 3 Schemes (4.87%)
Held by 42 FIIs (0.99%)
Ashishbhai Natawarlal Soparkar (14.65%)
Bandhan Small Cap Fund (2.95%)
18.28%
Quarterly Results Snapshot (Consolidated) - Sep'26 - QoQ
QoQ Growth in quarter ended Sep 2026 is 5.76% vs -4.18% in Jun 2026
QoQ Growth in quarter ended Sep 2026 is -34.75% vs 23.21% in Jun 2026
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is -6.53% vs 36.89% in Sep 2024
Growth in half year ended Sep 2025 is 26.76% vs 140.53% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'25
YoY Growth in nine months ended Dec 2025 is -6.84% vs 36.88% in Dec 2024
YoY Growth in nine months ended Dec 2025 is -7.30% vs 128.37% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is -0.90% vs 32.19% in Mar 2025
YoY Growth in year ended Mar 2026 is -7.19% vs 82.62% in Mar 2025